PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine

International Journal of Pharmaceutics

Volumn 443, Issue 1-2, 2013, Pages 68-79

  Regnier Delplace, C ^a,b   Thillaye Du Boullay, O ^c   Siepmann, F ^a,b   Martin Vaca, B ^c   Degrave, N ^a,b   Demonchaux, P ^d   Jentzer, O ^d   Bourissou, D ^c   Siepmann, J ^a,b  

^a UNIV LILLE   (France)

^b France   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d Minakem ^*  (France)

Author keywords

Apomorphine; Controlled release; Microparticle; Parkinson's disease; PLGA

Indexed keywords

ACETYLSALICYLIC ACID; APOMORPHINE; ASCORBIC ACID; POLYGLACTIN;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; EVAPORATION; EXTRACTION; GAS CHROMATOGRAPHY; LASER DIFFRACTION; OXIDATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANTIPARKINSON AGENTS; APOMORPHINE; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE PROPERTIES; X-RAY DIFFRACTION;

EID: 84873045591     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.01.008     Document Type: Article

References (53)

1. J.M. Anderson, and M.S. Shive Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Deliv. Rev. 28 1997 5 24
2. J. Armstrong, and R.B. Barlow The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants Brit. J. Pharmacol. 57 1976 501 516
3. A. Aubert-Pouessel, D.C. Bibby, M.C. Venier-Julienne, F. Hindré, and J.P. Benoit A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres Pharm. Res. 19 2002 1046 1051
4. A. Barbeau, H. Mars, M.I. Botez, and M. Joubert Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease Can. Med. Assoc. J. 106 1972 1169 1174
5. D.T. Birnbaum, J.D. Kosmala, D.B. Henthorn, and L. Brannon-Peppas Controlled release of β-estradiol from PLAGA microparticles: the effect of organic phase solvent on encapsulation and release J. Control. Release 65 2000 375 387
6. A.M. Burkman Some kinetic and thermodynamic characteristics of apomorphine degradation J. Pharm. Sci. 54 1965 325 326
7. J.J. Chen, and C. Obering A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease Clin. Ther. 27 2005 1710 1724
8. H.S. Choi, S.A. Seo, G. Khang, J.M. Rhee, and H.B. Lee Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles Int. J. Pharm. 234 2002 195 203
9. D. Cosco, R. Molinaro, V.M. Morittu, F. Cilurzo, N. Costa, and M. Fresta Anticancer activity of 9-cis-retinoic acid encapsulated in PEG-coated PLGA-nanoparticles J. Drug Deliver. Sci. Technol. 21 2011 395 400
10. M.A. Darbandi, and M. Zandkarimi Inhalable sustained release rifampicin microparticles: preparation and evaluation of in vitro and in vivo deposition J. Drug Deliver. Sci. Technol. 22 2012 175 179
11. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
12. C. Delplace, F. Kreye, D. Klose, F. Danede, M. Descamps, J. Siepmann, and F. Siepmann Impact of the experimental conditions on drug release from parenteral depot systems: from negligible to significant Int. J. Pharm. 432 2012 11 22
13. S.A. Factor Dopamine agonists Med. Clin. North Am. 83 1999 415 443
14. S. Fredenberg, M. Wahlgren, M. Reslow, and A. Axelsson The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review Int. J. Pharm. 415 2011 34 52
15. S. Freiberg, and X.X. Zhu Polymer microspheres for controlled drug release Int. J. Pharm. 282 2004 1 18
16. S. Freitas, H.P. Merkle, and B. Gander Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology J. Control. Release 102 2005 313 332
17. A. Gaignaux, J. Reeff, F. Siepmann, J. Siepmann, C. De Vriese, J. Goole, and K. Amighi Development and evaluation of sustained-release clonidine-loaded PLGA microparticles Int. J. Pharm. 437 2012 20 28
18. S.T. Gancher, W.R. Woodward, B. Boucher, and J.G. Nutt Peripheral pharmacokinetics of apomorphine in humans Ann. Neurol. 26 1989 232 238
19. J.M.P.J. Garrido, C. Delerue-Matos, M.F.M. Borges, T.R.A. Macedo, and A.M. Oliveira-Brett Oxidative behaviour of apomorphine and its metabolites Bioelectrochemistry 55 2002 113 114
20. J. Goole, and K. Amighi Levodopa delivery systems for the treatment of Parkinson's disease: an overview Int. J. Pharm. 380 2009 1 15
21. T.L. Hwang, Y.K. Lin, C.H. Chi, T.H. Huang, and J.Y. Fang Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery J. Pharm. Sci. 98 2009 3735 3747
22. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials 21 2000 2475 2490
23. P.N. Kaul, and E. Brochmann-Hanssen Auto-oxidation of apomorphine J. Pharm. Sci. 50 1961 266 267
24. H. Kranz, and R. Bodmeier A novel in situ forming drug delivery system for controlled parenteral drug delivery Int. J. Pharm. 332 2007 107 114
25. H.J. Lee, G. Riley, O. Johnson, J.L. Cleland, N. Kim, M. Charnis, L. Bailey, E. Duenas, A. Shahzamani, M. Marian, A.J.S. Jones, and S.D. Putney In vivo characterization of sustained-release formulations of human growth hormone J. Pharmacol. Exp. Ther. 281 1997 1431 1439
26. P.A. LeWitt Subcutaneously administered apomorphine - pharmacokinetics and metabolism Neurology 62 Suppl. 4 2004 S8 S11
27. W.I. Li, K.W. Anderson, R.C. Mehta, and P.P. DeLuca Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method J. Control. Release 37 1995 199 214
28. G.L. Li, M. Danhof, and J.A. Bouwstra Iontophoretic delivery of apomorphine in vitro: physicochemic considerations Pharm. Res. 18 2001 1509 1513
29. X. Luan, M. Skupin, J. Siepmann, and R. Bodmeier Key parameters affecting the initial release (burst) and encapsulation efficiency of peptide-containing poly(lactide-co-glycolide) microparticles Int. J. Pharm. 324 2006 168 175
30. H.K. Makadia, and S.J. Siegel Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier Polymers 3 2011 1377 1397
31. S. Mao, Y. Shi, L. Li, J. Xu, A. Schaper, and T. Kissel Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method Eur. J. Pharm. Biopharm. 68 2008 214 223
32. J.C. Middleton, and A.J. Tipton Synthetic biodegradable polymers as orthopedic devices Biomaterials 21 2000 2335 2346
33. 2-adrenoceptor J. Pharmacol. Exp. Ther. 303 2002 805 814
34. N.M.K. Ng Ying Kin, S. Lal, and J.X. Thavundayil Stability of apomorphine hydrochloride in aqueous sodium bisulphite solutions Prog. Neuro- Psychopharmacol. Biol. Psychiat. 25 2001 1461 1468
35. C. Olea-Azar, J. Alarcon, L. Opazo, B. Abarca, R. Ballesteros, and P. Bielsa Electron spin resonance and electrochemical studies of oxidation products derivates of apomorphine in aprotic solvents Bol. Soc. Chil. Quim. 47 2002 379 384
36. R. Pahwa, and K.E. Lyons Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review Neurol. Clin. 22 Suppl. 3 2004 S35 S52
37. W. Raasch, C. Slotty, and P. Dominiak In vitro and in vivo long term release of apomorphine from polymer matrices Jpn. J. Pharmacol. 84 2000 36 43
38. ® microspheres Int. J. Pharm. 434 2012 115 121
39. A. Rawat, and D. Burgess Effect of physical ageing on the performance of dexamethasone loaded PLGA microspheres Int. J. Pharm. 415 2011 164 168
40. Regnier-Delplace, C., Thillaye du Boullay, O., Siepmann, F., Martin-Vaca, B., Demonchaux, P., Jentzer, O., Danède, F., Descamps, M., Siepmann, J., Bourissou, D. PLGAs bearing carboxylated side chains: novel matrix formers with improved properties for controlled drug delivery, J. Control. Release, http://dx.doi.org/10.1016/j.jconrel.2012.12.024, in press.
41. P. Sansdrap, and A.J. Moës Influence of manufacturing parameters on the size characteristics and the release profiles of nifedipine from poly(d,l-lactide-co-glycolide) microspheres Int. J. Pharm. 98 1993 157 164
42. K. Schoenhammer, H. Petersen, F. Guethlein, and A. Goepferich Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability Int. J. Pharm. 371 2009 33 39
43. C. Slotty, W. Raasch, U. Schramm, B. Sabel, and P. Dominiak In vitro release of apomorphine from polymere matrices Pharm. Pharmacol. Lett. 2 1995 83 86
44. M. Stacy, and D. Silver Apomorphine for the acute treatment of "off" episodes in Parkinson's disease Parkinsonism Relat. Disord. 14 2008 85 92
45. C.M. Stibe, P.A. Kempster, A.J. Lees, and G.M. Stern Subcutaneous apomorphine in Parkinsonian on-off oscillations Lancet 1 1988 403 406
46. J.A. Subramony Apomorphine in dopaminergic therapy Mol. Pharm. 3 2006 380 385
47. C. Thomasin, H. Nam-Trân, H.P. Merkle, and B. Gander Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 1. Overview and theoretical considerations J. Pharm. Sci. 87 1998 259 268
48. R. Van der Geest, P. Kruger, J.M. Gubbens-Stibbe, T. van Laar, H.E. Bodde, and M. Danhof Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease J. Chromatogr. B 702 1997 131 141
49. R.E. Wilcox, D.W. Humphrey, W.H. Riffee, and R.V. Smith Stability of apomorphine in solutions containing ascorbic acid and bisulfite and effects of antioxidants on apomorphine-induced cage climbing and hypothermia in mice J. Pharm. Sci. 69 1980 974 976
50. C. Wischke, and S.P. Schwendeman Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles Int. J. Pharm. 364 2008 298 327
51. Q. Yang, R. Reams, and G. Owusu-Ababio Effect of solvent composition during preparation on the characteristics of enoxacin microparticles J. Pharm. Pharmacol. 51 1999 659 665
52. Q. Yang, and G. Owusu-Ababio Biodegradable progesterone microsphere delivery system for osteoporosis therapy Drug Dev. Ind. Pharm. 26 2000 61 70
53. H. Zhang, Y. Lu, G. Zhang, S. Gao, D. Sun, and Y. Zhong Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres. I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release Int. J. Pharm. 351 2008 244 249